# Kumorixilib Plus Capecitabine and Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast Cancer

> **NCT07691333** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 35 (estimated)

## Conditions studied

- HR+/HER2- Breast Cancer
- Breast Neoplasms

## Interventions

- **DRUG:** Kumorixilib 180mg
- **DRUG:** Capecitabine 500mg
- **DRUG:** Letrozole 2.5mg

## Key facts

- **NCT ID:** NCT07691333
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2028-01-30
- **Final completion:** 2028-04-30
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07691333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07691333, "Kumorixilib Plus Capecitabine and Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07691333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*